Need a dislike button for this!

Sorry to hear this.

the tens of thousands who suffer from the illness, especially in African nations where the disease is prevalent. You can read all this and more here:
• www.cbsnews.com/newyork/news...
• www.yahoo.com/news/long-is...
• www.nhlbi.nih.gov/health/sickl...
• www.fda.gov/news-events/...
• www.lyfgenia.com

is also looking to re-enroll in school to pursue a medical career, inspired by his own journey. Contributions have been made to Northwell Health, supporting the organization's continuing efforts in treating sickle cell disease, a move that signifies hope for the availability of the gene therapy for

had to stay in the hospital for about another month and said that January 13th was the day he felt like a new person as things kicked in. Beauzile says he’s not in pain anymore, and that he’s been able to do a lot of new things, including finally having the first chance for a carefree vacation. He

In late December, Sebastien’s stem cells were successfully re-infused back into him in a matter of minutes. Now he’s producing normal adult hemoglobin in his parent cells and that’s why he’s not having any symptoms related to his sickle cell disease according to his doctors. For assurances, Beauzile

treated with Lyfgenia in the lab before being infused back via a stem cell transplant. Before the procedure, the patient must undergo a round of high-dose chemotherapy to eliminate faulty blood stem cells and make room for new ones.

patient, and creates a new, healthy gene inserted into parent cells that connect to the stem cells of red blood cells afflicted by the illness instead of more painful procedures like bone marrow transplants. Patients’ own hematopoietic stem cells, or blood cell precursors, are collected and then

treatment of sickle cell disease in patients 12 years of age and older with a history of vaso-occlusive events (VOEs). Lyfgenia delivers a modified version of the HBB gene that can produce a form of hemoglobin (HbAT87Q) that’s resistant to clumping or sickling. It is made SPECIFICALLY for each

was FDA approved in late 2023, Sebastien was the first patient on their minds, and it changed his life dramatically. Lyfgenia is a one-time gene therapy used to treat sickle cell disease in patients 12 years of age or older and a history of vaso-occlusive events. It was approved by the FDA for the

Northwell facility in New Hyde Park. He couldn’t travel without going to a hospital, had a hard time working a job, and had to stop going to Queens Community College because of recurring issues with the disease, which made his life substantially challenging. When Lyfgenia became available when it

and intense pain if damaged red blood cells block vessels and restrict oxygen supply, which can also lead to strokes and heart failure. Beauzile, had his first of many crises from his extremely severe case of sickle cell as a 4-month-old baby. Since then, he has consistently been in and out of the

mutation (mutation in the HBB gene) causes red blood cells to become irreversibly sickle shaped, which can lead to haemolytic anaemia- a blood condition that occurs when your red blood cells are destroyed faster than they are replaced. Over a long period, the disorder can cause severe organ damage

descent. According to the center’s Director of Pediatric Hematology, Oncology, and Stem Cell Transplantation: THIS IS A FIX. Other drugs modify the disease, but this is a CURE and they suspect this genetic treatment will replace bone marrow transplants in time. In sickle cell disease, a gene

In a significant medical breakthrough, Long Island's Sebastien Beauzile has become the first person in New York to be cured of sickle cell anemia, a genetic disease that causes chronic pain and a host of other health issues, primarily affecting people of African, Mediterranean, and Middle Eastern